Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Adamis Pharmaceuticals : Announces Results of 2021 Annual Meeting of Stockholders

07/19/2021 | 04:06pm EDT

Based on Results Provided by the Inspector of Election, Stockholders Re-Elected All Five Members of the Company's Board of Directors

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced that based on the Inspector of Election’s certified results from the Company’s 2021 Annual Meeting of Stockholders (the “Annual Meeting”), each of the Company’s nominees – Howard C. Birndorf, Roshawn A. Blunt, Dennis J. Carlo, Ph.D., David J. Marguglio and Richard C. Williams – have been re-elected to the Board of Directors (the "Board"). According to the Inspector of Election’s report, stockholders approved all other proposals considered at the Annual Meeting, including the approval on an advisory basis of the compensation paid to named executive officers and the ratification on an advisory basis of the appointment of our registered public accounting firm BDO USA, LLP for 2021. The Board thanks the Adamis stockholders for their engagement and support.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The Company’s SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis’ naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, and radiation dermatitis. The company’s subsidiary, US Compounding Inc. (“USC”), compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. For additional information about Adamis Pharmaceuticals, please visit www.adamispharmaceuticals.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited to the following statements: the Company’s beliefs concerning the safety and effectiveness of its products and product candidates; the Company’s ability to successfully commercialize the products and product candidates described in this press release, itself or through commercialization partners, and the Company’s beliefs concerning the commercial success of its products; and other statements concerning our future operations, activities and financial results. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, which may cause Adamis’ actual results to be materially different from the results anticipated by such forward-looking statements. We cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this press release. Certain of these risks and additional risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, including its annual report on Form 10-K for the year ended December 31, 2020 and subsequent filings with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC's web site at http://www.sec.gov.


© Business Wire 2021
All news about ADAMIS PHARMACEUTICALS CORPORATION
09/13ADAMIS PHARMACEUTICALS : Departure of Directors of Certain Officers; Election of..
PU
09/13ADAMIS PHARMACEUTICALS CORP : Change in Directors or Principal Officers (form 8-..
AQ
09/13Adamis Pharmaceuticals Corporation Announces Resignation of Roshawn A. Blunt ..
CI
09/02ADAMIS PHARMACEUTICALS : Begins Dosing Patients in Phase 2/3 Trial of Tempol to ..
MT
09/02Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for T..
GL
09/02Adamis Pharmaceuticals Corporation Doses First Patients in Phase 2/3 Clinical..
CI
08/30NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
08/24ADAMIS PHARMACEUTICALS : 8-K (Form 8-K)
PU
08/24ADAMIS PHARMACEUTICALS CORP : Notice of Delisting or Failure to Satisfy a Contin..
AQ
08/24ADAMIS PHARMACEUTICALS : Names New CFO
MT
More news
Financials (USD)
Sales 2021 22,0 M - -
Net income 2021 -24,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,47x
Yield 2021 -
Capitalization 164 M 164 M -
Capi. / Sales 2021 7,44x
Capi. / Sales 2022 16,4x
Nbr of Employees 130
Free-Float 98,6%
Chart ADAMIS PHARMACEUTICALS CORPORATION
Duration : Period :
Adamis Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 1,10 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Dennis J. Carlo President, Chief Executive Officer & Director
David C. Benedicto Chief Financial & Accounting Officer
Richard C. Williams Chairman
Ronald B. Moss Chief Medical Officer
Karen K. Daniels Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ADAMIS PHARMACEUTICALS CORPORATION126.76%164
JOHNSON & JOHNSON4.98%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.21.62%249 329
NOVO NORDISK A/S51.34%233 887
ELI LILLY AND COMPANY36.84%209 456